$NB
NIOCORP DEVELOPMENTS LTD Stock $nb

$nb Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000153949724002408 Filed on November 13, 2024

Income Statement

Concept	2024 Q4	2024 Q3
Revenue		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin		$780.0K
YoY Change		-48.34%
% of Gross Profit
Research & Development		$138.0K
YoY Change		-87.45%
% of Gross Profit
Depreciation & Amortization		$1.000K
YoY Change		0.0%
% of Gross Profit
Operating Expenses		$1.395M
YoY Change		-59.48%
Operating Profit
YoY Change
Interest Expense		-$44.00K
YoY Change		-102.12%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income		-$2.102M
YoY Change		-39.77%
Income Tax
% Of Pretax Income
Net Earnings		-$2.102M
YoY Change		-37.94%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share		-$0.05
COMMON SHARES
Basic Shares Outstanding	42.51M shares	38.66M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q4	2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$150.0K
YoY Change		-86.36%
Cash & Equivalents		$150.0K
Short-Term Investments
Other Short-Term Assets		$1.046M
YoY Change		7.84%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets		$1.196M
YoY Change		-42.11%
LONG-TERM ASSETS
Property, Plant & Equipment		$17.09M
YoY Change		-0.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$4.000K
YoY Change		-60.0%
Other Assets		$35.00K
YoY Change		-12.5%
Total Long-Term Assets		$17.13M
YoY Change		-0.36%
TOTAL ASSETS
Total Short-Term Assets		$1.196M
Total Long-Term Assets		$17.13M
Total Assets		$18.32M
YoY Change		-4.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$2.736M
YoY Change		-24.32%
Accrued Expenses		$777.0K
YoY Change		-33.59%
Deferred Revenue
YoY Change
Short-Term Debt		$33.00K
YoY Change
Long-Term Debt Due		$5.258M
YoY Change		-23.91%
Total Short-Term Liabilities		$8.124M
YoY Change		-35.3%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00
YoY Change
Other Long-Term Liabilities		$1.595M
YoY Change		-48.52%
Total Long-Term Liabilities		$1.595M
YoY Change		-48.52%
TOTAL LIABILITIES
Total Short-Term Liabilities		$8.124M
Total Long-Term Liabilities		$1.595M
Total Liabilities		$14.44M
YoY Change		-40.42%
SHAREHOLDERS EQUITY
Retained Earnings		-$164.0M
YoY Change		6.7%
Common Stock		$167.3M
YoY Change		13.26%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$2.381M
YoY Change
Total Liabilities & Shareholders Equity		$18.32M
YoY Change		-4.84%

Cashflow Statement

Concept	2024 Q4	2024 Q3
OPERATING ACTIVITIES
Net Income		-$2.102M
YoY Change		-37.94%
Depreciation, Depletion And Amortization		$1.000K
YoY Change		0.0%
Cash From Operating Activities		-$642.0K
YoY Change		-76.54%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-$1.220M
YoY Change		-181.66%
NET CHANGE
Cash From Operating Activities		-$642.0K
Cash From Investing Activities
Cash From Financing Activities		-$1.220M
Net Change In Cash		-$1.862M
YoY Change		49.8%
FREE CASH FLOW
Cash From Operating Activities		-$642.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2024Q3	dei	Amendment Flag AmendmentFlag	false
CY2024Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024Q3	dei	Entity Central Index Key EntityCentralIndexKey	0001512228
CY2024Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2024Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q3	dei	Entity File Number EntityFileNumber	001-41655
CY2024Q3	dei	Entity Registrant Name EntityRegistrantName	NioCorp Developments Ltd.
CY2024Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1262185
CY2024Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	7000 South Yosemite Street
CY2024Q3	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 115
CY2024Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Centennial
CY2024Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2024Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80112
CY2024Q3	dei	City Area Code CityAreaCode	(720)
CY2024Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q3	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	42512202	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2012000	usd
CY2024Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	330000	usd
CY2023Q3	us-gaap	Professional Fees ProfessionalFees	1187000	usd
CY2024Q3	dei	Document Type DocumentType	10-Q
CY2024Q2	us-gaap	Deferred Finance Costs Ownshare Lending Arrangement Issuance Costs Gross DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsGross		usd
CY2024Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2024Q2	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities		usd
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2023Q3	niobf	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes		usd
CY2023Q3	us-gaap	Other Income OtherIncome		usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	niobf	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote		usd
CY2023Q3	niobf	Otheroperating Gains Losses OtheroperatingGainsLosses		usd
CY2024Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments		usd
CY2023Q3	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
CY2023Q3	niobf	Value Of Warrants Issued ValueOfWarrantsIssued		usd
CY2024Q3	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2102000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3387000	usd
CY2024Q3	us-gaap	Convertible Debt ConvertibleDebt		usd
CY2024Q3	us-gaap	Nonmonetary Transaction Gain Loss Recognized On Transfer NonmonetaryTransactionGainLossRecognizedOnTransfer		usd
CY2024Q3	us-gaap	Nonmonetary Transaction Gain Loss Recognized On Transfer NonmonetaryTransactionGainLossRecognizedOnTransfer		usd
CY2024Q3	us-gaap	Nonmonetary Transaction Gain Loss Recognized On Transfer NonmonetaryTransactionGainLossRecognizedOnTransfer		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y2M19D
CY2024Q3	niobf	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised		shares
CY2024Q3	niobf	Class Of Warrant Or Right Exercise Price Exercised ClassOfWarrantOrRightExercisePriceExercised		shares
CY2024Q3	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024Q3	dei	Local Phone Number LocalPhoneNumber	334-7066
CY2024Q3	us-gaap	Deferred Finance Costs Ownshare Lending Arrangement Issuance Costs Gross DeferredFinanceCostsOwnshareLendingArrangementIssuanceCostsGross	459000	usd
CY2024Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	587000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	916000	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1196000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	2928000	usd
CY2024Q3	us-gaap	Deposits Assets DepositsAssets	35000	usd
CY2024Q2	us-gaap	Deposits Assets DepositsAssets	35000	usd
CY2024Q3	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	4000	usd
CY2024Q2	us-gaap	Long Term Investments And Receivables Net LongTermInvestmentsAndReceivablesNet	4000	usd
CY2024Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	167000	usd
CY2024Q2	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	181000	usd
CY2024Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	836000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	837000	usd
CY2024Q3	us-gaap	Capitalized Costs Mineral Interests In Unproved Properties CapitalizedCostsMineralInterestsInUnprovedProperties	16085000	usd
CY2024Q2	us-gaap	Capitalized Costs Mineral Interests In Unproved Properties CapitalizedCostsMineralInterestsInUnprovedProperties	16085000	usd
CY2024Q3	us-gaap	Assets Assets	18323000	usd
CY2024Q2	us-gaap	Assets Assets	20070000	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2736000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1843000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2365000	usd
CY2024Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	5258000	usd
CY2024Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	7660000	usd
CY2024Q3	us-gaap	Related Party Deposit Liabilities RelatedPartyDepositLiabilities	33000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	97000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	96000	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8124000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11964000	usd
CY2024Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1595000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1651000	usd
CY2024Q3	niobf	Earnout Liability At Fair Value EarnoutLiabilityAtFairValue	4633000	usd
CY2024Q2	niobf	Earnout Liability At Fair Value EarnoutLiabilityAtFairValue	3817000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	104000	usd
CY2024Q3	us-gaap	Liabilities Liabilities	14439000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	17536000	usd
CY2024Q3	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1503000	usd
CY2024Q2	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	1534000	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38720244	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38062647	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	167275000	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	163823000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163983000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-161912000	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-911000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-911000	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	2381000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	1000000	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18323000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20070000	usd
CY2023Q3	us-gaap	Labor And Related Expense LaborAndRelatedExpense	322000	usd
CY2024Q3	us-gaap	Professional Fees ProfessionalFees	450000	usd
CY2024Q3	niobf	Exploration Expenditures ExplorationExpenditures	138000	usd
CY2023Q3	niobf	Exploration Expenditures ExplorationExpenditures	1100000	usd
CY2024Q3	us-gaap	Other General Expense OtherGeneralExpense	477000	usd
CY2023Q3	us-gaap	Other General Expense OtherGeneralExpense	834000	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	1395000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	3443000	usd
CY2024Q3	niobf	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-816000	usd
CY2023Q3	niobf	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	2093000	usd
CY2024Q3	niobf	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-56000	usd
CY2023Q3	niobf	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	73000	usd
CY2024Q3	niobf	Change In Fair Value Of Convertible Notes ChangeInFairValueOfConvertibleNotes	-17000	usd
CY2024Q3	us-gaap	Interest Expense InterestExpense	-44000	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	-2075000	usd
CY2024Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	8000	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-11000	usd
CY2024Q3	us-gaap	Other Income OtherIncome	-122000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax	1000	usd
CY2024Q3	niobf	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest1 IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1	-2102000	usd
CY2023Q3	niobf	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest1 IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1	-3488000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	101000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2102000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3387000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	31000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	174000	usd
CY2024Q3	us-gaap	Oci Equity Method Investment Before Tax Parent OciEquityMethodInvestmentBeforeTaxParent	-2071000	usd
CY2023Q3	us-gaap	Oci Equity Method Investment Before Tax Parent OciEquityMethodInvestmentBeforeTaxParent	-3213000	usd
CY2024Q3	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	-0.05
CY2023Q3	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	-0.09
CY2024Q3	niobf	Total Weighted Average Number Of Share Outstanding Basic And Diluted TotalWeightedAverageNumberOfShareOutstandingBasicAndDiluted	38361344	shares
CY2023Q3	niobf	Total Weighted Average Number Of Share Outstanding Basic And Diluted TotalWeightedAverageNumberOfShareOutstandingBasicAndDiluted	31967091	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-2102000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3387000	usd
CY2024Q3	niobf	Change In Fair Value Of Earnout Share Liability ChangeInFairValueOfEarnoutShareLiability	816000	usd
CY2023Q3	niobf	Change In Fair Value Of Earnout Share Liability ChangeInFairValueOfEarnoutShareLiability	-2093000	usd
CY2024Q3	niobf	Change In Valuation Of Warrant Liabilities ChangeInValuationOfWarrantLiabilities	-56000	usd
CY2023Q3	niobf	Change In Valuation Of Warrant Liabilities ChangeInValuationOfWarrantLiabilities	73000	usd
CY2024Q3	niobf	Change In Fair Value Of Convertible Note ChangeInFairValueOfConvertibleNote	17000	usd
CY2024Q3	us-gaap	Accretion Expense AccretionExpense	44000	usd
CY2023Q3	us-gaap	Accretion Expense AccretionExpense	2075000	usd
CY2024Q3	niobf	Otheroperating Gains Losses OtheroperatingGainsLosses	122000	usd
CY2024Q3	niobf	Fair Value Of Commitment Shares Issued FairValueOfCommitmentSharesIssued	-1000	usd
CY2023Q3	niobf	Fair Value Of Commitment Shares Issued FairValueOfCommitmentSharesIssued	53000	usd
CY2024Q3	us-gaap	Depreciation Depreciation	1000	usd
CY2023Q3	us-gaap	Depreciation Depreciation	1000	usd
CY2023Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1000	usd
CY2024Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	-1000	usd
CY2023Q3	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	-1000	usd
CY2024Q3	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-1404000	usd
CY2023Q3	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-3278000	usd
CY2024Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	130000	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-417000	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	892000	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	124000	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-642000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2737000	usd
CY2024Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	692000	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1532000	usd
CY2024Q3	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	33000	usd
CY2024Q3	us-gaap	Repayments Of Debt RepaymentsOfDebt	1943000	usd
CY2024Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2000	usd
CY2023Q3	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	38000	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1220000	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1494000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1862000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1243000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2012000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2341000	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	150000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1098000	usd
CY2024Q3	niobf	Conversions Of Debt For Common Shares ConversionsOfDebtForCommonShares	501000	usd
CY2023Q3	niobf	Conversions Of Debt For Common Shares ConversionsOfDebtForCommonShares	5729000	usd
CY2024Q3	niobf	Value Of Warrants Issued ValueOfWarrantsIssued	2262000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10967000	usd
CY2023Q3	niobf	Private Placement Value PrivatePlacementValue	1000000	usd
CY2023Q3	niobf	Shares Issued Under The Yorkville Equity Facility SharesIssuedUnderTheYorkvilleEquityFacility	585000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	5729000	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-38000	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3213000	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-6904000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1000000	usd
CY2024Q3	niobf	Shares Issued Under The Yorkville Equity Facility SharesIssuedUnderTheYorkvilleEquityFacility	691000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	501000	usd
CY2024Q3	niobf	Stock Issued During Period Value Issuance Of Financing Warrants StockIssuedDuringPeriodValueIssuanceOfFinancingWarrants	2262000	usd
CY2024Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	-2000	usd
CY2024Q3	us-gaap	Profit Loss ProfitLoss	-2071000	usd
CY2024Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	2381000	usd
CY2024Q3	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80F_eus-gaap--NatureOfOperations_zYOu73kDNj1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_82C_zG0C54Bd2Ow7">DESCRIPTION OF BUSINESS</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NioCorp Developments Ltd. (“we,” “us,” “our,” “NioCorp” or the “Company”) was incorporated on February 27, 1987, under the laws of the Province of British Columbia and currently operates in <span id="xdx_903_eus-gaap--NumberOfReportableSegments_dxL_uNumber_c20240701__20240930_zMxz1FFDWmP7" title="Number of reportable segments::XDX::1"><span style="-sec-ix-hidden: xdx2ixbrl0409">one</span></span> reportable operating segment consisting of exploration and development of mineral deposits in North America, specifically, the Company’s niobium, scandium, and titanium project (the “Elk Creek Project”) located in southeastern Nebraska.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These interim condensed consolidated financial statements have been prepared on a going concern basis that contemplates the realization of assets and discharge of liabilities at their carrying values in the normal course of business for the foreseeable future. These financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently earns no operating revenues and will require additional capital in order to advance the Elk Creek Project to construction and commercial operation. As further discussed in Note 3, these matters raised substantial doubt about the Company’s ability to continue as a going concern, and the Company is dependent upon the generation of profits from mineral properties, obtaining additional financing and maintaining continued support from its shareholders and creditors. </span></p>
CY2024Q3	us-gaap	Basis Of Accounting BasisOfAccounting	<p id="xdx_80D_eus-gaap--BasisOfAccounting_zysVj0Atdfwj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_827_zmncpzFAIFK6">BASIS OF PRESENTATION</span></span></td></tr> </table> <p id="xdx_848_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zAS8vA0YxUC9" style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_868_zbG62WJMUltc">Basis of Presentation and Consolidation</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles of the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). The interim condensed consolidated financial statements include the consolidated accounts of the Company and its wholly owned subsidiaries with all significant intercompany transactions eliminated. The accounting policies followed in preparing these interim condensed consolidated financial statements are those used by the Company as set out in the audited consolidated financial statements for the year ended June 30, 2024. Certain transactions include reference to Canadian dollars (“C$”) where applicable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the opinion of management, all adjustments considered necessary (including normal recurring adjustments) for a fair statement of the financial position, results of operations, and cash flows at September 30, 2024, and for all periods presented, have been included in these interim condensed consolidated financial statements. Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to appropriate SEC rules and regulations. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended June 30, 2024. The interim results are not necessarily indicative of results for the full year ending June 30, 2025, or future operating periods.</span></p> <p id="xdx_851_zvMgGNB4otD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"> </span></p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zOCmPn7lNNj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86E_z3UoeJf1dJM6">Recent Accounting Standards</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Issued and Not Effective</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) that are adopted by the Company as of the specified effective date. Unless otherwise discussed, management believes that the impact of recently issued standards did not or will not have a material impact on the Company’s consolidated financial statements upon adoption.</span></p> <p id="xdx_85A_z3GFShKbKQyh" style="font: 1pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p id="xdx_842_eus-gaap--UseOfEstimates_z3SiY5w94AGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_z5OQnemVNJh9">Use of Estimates</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the carrying value of long-term assets, deferred income tax assets and related valuations, liabilities related to the April 2024 Notes, Earnout Shares, Private Warrants, and Contingent Consent Warrants (each, as defined below), and share-based compensation. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between estimates and the actual results, future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company acquired a federal income tax payable of $<span id="xdx_90D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20240701__20240930_zlBtMPIJ1op1" title="Federal income tax payable">443</span> in connection with the GXII Transaction (as defined below). As a result of post-transaction losses at Elk Creek Resources Corp. (“ECRC”), a partial release of the valuation allowance attributed to the reduction of the acquired federal income tax payable of $<span id="xdx_90B_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_c20230701__20230930_zPdI1r0unlw8" title="Income tax payable">101</span> was recorded as an income tax benefit in the condensed consolidated statement of operations and comprehensive loss for the three months ended September 30, 2023. The Company maintains a full valuation allowance against future income tax assets as it is more likely than not that all of the assets will not be realized. </span></p> <p id="xdx_850_zdE5GLaBrof5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"> </span></p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zDPbzauHgqsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86C_z6q9i4Iyxf9j">Basic and Diluted Earnings per Share</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p id="xdx_89C_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zsGGon4HYLmh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company utilizes the weighted average method to determine the impact of changes in a participating security on the calculation of loss per share. <span id="xdx_8BF_z4l8xyzsUWA6">The following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common shareholders:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-size: 1pt"> </span></td><td><span style="font-size: 1pt"> </span></td> <td style="text-align: center"><span style="font-size: 1pt"> </span></td> <td style="text-align: center"><span style="font-size: 1pt"> </span></td> <td style="text-align: center"><span style="font-size: 1pt"> </span></td> <td style="text-align: center"><span style="font-size: 1pt"> </span></td> <td style="text-align: center"><span style="font-size: 1pt"> </span></td> <td style="text-align: center"><span style="font-size: 1pt"> </span></td><td><span style="font-size: 1pt"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months <br/>Ended September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: justify; padding-left: 0.125in">Net loss</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--NetIncomeLoss1_pn3n3_c20240701__20240930_zXURRH4Zq1Qf" style="width: 12%; text-align: right" title="Net loss">(2,102</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--NetIncomeLoss1_pn3n3_c20230701__20230930_z3Nbict3AAE9" style="width: 12%; text-align: right" title="Net loss">(3,387</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0.125in">Less: Net loss attributable to noncontrolling interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_c20240701__20240930_zFzHDQM6k5Pj" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Net loss attributable to noncontrolling interest">(31</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98F_eus-gaap--NetIncomeLossAttributableToNoncontrollingInterest_iN_pn3n3_di_c20230701__20230930_zrbmEO99sj22" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Net loss attributable to noncontrolling interest">(174</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 0.125in">Net loss available to participating securities</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20240701__20240930_zO1oS9kkliB7" style="text-align: right" title="Net loss available to participating securities">(2,071</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_pn3n3_c20230701__20230930_zBwJ4DnmPTml" style="text-align: right" title="Net loss available to participating securities">(3,213</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 0.125in">Less: Net loss attributable to vested shares of ECRC Class B common stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_pn3n3_c20240701__20240930_zOffFp98jZoe" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Net loss attributable to vested shares of ECRC Class B common stock">(186</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_pn3n3_c20230701__20230930_zbjS9KFiAS9" style="border-bottom: Black 1pt solid; text-align: right" title="Less: Net loss attributable to vested shares of ECRC Class B common stock">(257</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2pt; padding-left: 0.125in">Net loss attributed to common shareholders - basic and diluted</td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_pn3n3_c20240701__20240930_z79TUoCxd7I6" style="border-bottom: Black 2pt solid; text-align: right" title="Net loss attributable to vested shares of ECRC Class B common stock">(1,885</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_pn3n3_c20230701__20230930_zU3Yo09f6yFl" style="border-bottom: Black 2pt solid; text-align: right" title="Net loss attributable to vested shares of ECRC Class B common stock">(2,956</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 0.125in">Weighted average shares outstanding – basic and diluted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_c20240701__20240930_zCjQCklwt7i1" style="text-align: right" title="Weighted average shares outstanding basic and diluted">38,361,344</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_uShares_c20230701__20230930_zocTkntBB0de" style="text-align: right" title="Weighted average shares outstanding basic and diluted">31,967,091</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 2pt; padding-left: 0.125in">Loss per Common Share outstanding – basic and diluted</td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt solid; text-align: left">$</td><td id="xdx_982_ecustom--EarningsLossPerShareBasicAndDiluted_pid_uUSDPShares_c20240701__20240930_zIGXkG54ss4" style="border-bottom: Black 2pt solid; text-align: right" title="Loss per common share outstanding basic and diluted">(0.05</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt solid; text-align: left">$</td><td id="xdx_980_ecustom--EarningsLossPerShareBasicAndDiluted_pid_uUSDPShares_c20230701__20230930_zfK9460Y3fkb" style="border-bottom: Black 2pt solid; text-align: right" title="Loss per common share outstanding basic and diluted">(0.09</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table> <p id="xdx_8AA_zkIsFeClJGA7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following common shares, no par value, of the Company (“Common Shares”) underlying options to purchase Common Shares (“Options”), Common Share purchase warrants (“Warrants”), and outstanding convertible debt were antidilutive due to a net loss in the periods presented and, therefore, were excluded from the dilutive securities computation for the three-month periods indicated below.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p> <p id="xdx_896_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_znZLZfAkFCH" style="font: 1pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span id="xdx_8BC_zhUeftbbcOy2" style="display: none; visibility: hidden">Schedule of excluded from the dilutive securities</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 1pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 94%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td> </td> <td colspan="6" style="text-align: center">For the Three Months <br/>Ended September 30,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td>Excluded potentially dilutive securities <sup id="xdx_F6F_zIte5Np7FUFf">(1)(2)</sup>:</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">2024</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: right">2023</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Options</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--IncrementalCommonSharesAttributableToWrittenPutOptions_pid_uShares_c20240701__20240930_fKDEpKDIp_zbrcgLpWgE6d" style="width: 12%; text-align: right" title="Options">2,455,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--IncrementalCommonSharesAttributableToWrittenPutOptions_pid_uShares_c20230701__20230930_fKDEpKDIp_z1MJsWfUsQR" style="width: 12%; text-align: right" title="Options">1,319,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_uShares_c20240701__20240930_fKDEpKDIp_zXvYfHZKQGNi" style="text-align: right" title="Warrants">20,932,985</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--IncrementalCommonSharesAttributableToCallOptionsAndWarrants_pid_uShares_c20230701__20230930_fKDEpKDIp_zNG0pUxA0mf7" style="text-align: right" title="Warrants">19,066,304</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Convertible debt</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_pid_uShares_c20240701__20240930_fKDEpKDIp_zAvLv9qp0eW6" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible debt">1,920,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--IncrementalCommonSharesAttributableToConversionOfDebtSecurities_pid_uShares_c20230701__20230930_fKDEpKDIp_zaVTCGQ29mda" style="border-bottom: Black 1pt solid; text-align: right" title="Convertible debt">2,448,730</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2pt">Total potential dilutive securities</td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt solid; padding-bottom: 2pt; text-align: left"> </td><td id="xdx_98D_eus-gaap--DilutiveSecurities_c20240701__20240930_fKDEpKDIp_zIbOnODh7Mgc" style="border-bottom: Black 2pt solid; text-align: right" title="Total potential dilutive securities">25,308,485</td><td style="padding-bottom: 2pt; text-align: left"> </td><td style="padding-bottom: 2pt"> </td> <td style="border-bottom: Black 2pt solid; padding-bottom: 2pt; text-align: left"> </td><td id="xdx_989_eus-gaap--DilutiveSecurities_c20230701__20230930_fKDEpKDIp_zvnMIq7Frfoj" style="border-bottom: Black 2pt solid; text-align: right" title="Total potential dilutive securities">22,834,034</td><td style="padding-bottom: 2pt; text-align: left"> </td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.375in"> </td> <td style="width: 0.375in; text-align: justify"><span id="xdx_F02_zjAwZAoQHD6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: justify"><span id="xdx_F18_zzr8bMTPhwY9" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The number of shares is based on the maximum number of shares issuable on exercise or conversion of the related securities as of the period end. Such amounts have not been adjusted for the treasury stock method or weighted average outstanding calculations as required if the securities were dilutive.</span></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span id="xdx_F0B_zvkAbz8xNUta" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: justify"><span id="xdx_F1A_zU6ppeYGWiRh" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnout Shares are excluded as the vesting terms were not met as of the end of the reporting period.</span></td></tr> </table> <p id="xdx_8AE_z1aDhns6aQ6k" style="margin-top: 0; margin-bottom: 0"><span style="font-size: 1pt"> </span></p> <p id="xdx_85A_zBEmehzoAVh8" style="margin-top: 0; margin-bottom: 0"><span style="font-size: 1pt"> </span></p>
CY2024Q3	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_842_eus-gaap--UseOfEstimates_z3SiY5w94AGe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="width: 0.25in; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td style="font-size: 10pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_86A_z5OQnemVNJh9">Use of Estimates</span></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the carrying value of long-term assets, deferred income tax assets and related valuations, liabilities related to the April 2024 Notes, Earnout Shares, Private Warrants, and Contingent Consent Warrants (each, as defined below), and share-based compensation. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between estimates and the actual results, future results of operations will be affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The Company acquired a federal income tax payable of $<span id="xdx_90D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_c20240701__20240930_zlBtMPIJ1op1" title="Federal income tax payable">443</span> in connection with the GXII Transaction (as defined below). As a result of post-transaction losses at Elk Creek Resources Corp. (“ECRC”), a partial release of the valuation allowance attributed to the reduction of the acquired federal income tax payable of $<span id="xdx_90B_eus-gaap--IncomeTaxExpenseBenefit_pn3n3_c20230701__20230930_zPdI1r0unlw8" title="Income tax payable">101</span> was recorded as an income tax benefit in the condensed consolidated statement of operations and comprehensive loss for the three months ended September 30, 2023. The Company maintains a full valuation allowance against future income tax assets as it is more likely than not that all of the assets will not be realized. </span></p>
CY2024Q3	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	443000	usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	101000	usd
CY2024Q3	niobf	Net Income Loss1 NetIncomeLoss1	-2102000	usd
CY2023Q3	niobf	Net Income Loss1 NetIncomeLoss1	-3387000	usd
CY2024Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	31000	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	174000	usd
CY2024Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2071000	usd
CY2023Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3213000	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-186000	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-257000	usd
CY2024Q3	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-1885000	usd
CY2023Q3	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-2956000	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38361344	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31967091	shares
CY2024Q3	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	-0.05
CY2023Q3	niobf	Earnings Loss Per Share Basic And Diluted EarningsLossPerShareBasicAndDiluted	-0.09
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	2455500	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Written Put Options IncrementalCommonSharesAttributableToWrittenPutOptions	1319000	shares
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	20932985	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	19066304	shares
CY2024Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	1920000	shares
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2448730	shares
CY2024Q3	us-gaap	Dilutive Securities DilutiveSecurities	25308485000	usd
CY2023Q3	us-gaap	Dilutive Securities DilutiveSecurities	22834034000	usd
CY2024Q3	us-gaap	Investment Company Distributable Earnings Loss Accumulated Capital Loss Carryforward InvestmentCompanyDistributableEarningsLossAccumulatedCapitalLossCarryforward	6928000	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163983000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	150000	usd
CY2024Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2056000	usd
CY2024Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1417000	usd
CY2024Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	603000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	350000	usd
CY2024Q3	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	48000	usd
CY2024Q2	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	48000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	29000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Fair Value Disclosure AccountsPayableAndAccruedLiabilitiesFairValueDisclosure	28000	usd
CY2024Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2736000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1843000	usd
CY2024Q2	us-gaap	Convertible Debt ConvertibleDebt	571000	usd
CY2024Q3	us-gaap	Accretion Expense Including Asset Retirement Obligations AccretionExpenseIncludingAssetRetirementObligations	43000	usd
CY2024Q3	niobf	Principal And Accrued Interest Converted PrincipalAndAccruedInterestConverted	-614000	usd
CY2024Q3	niobf	Contractual Interest ContractualInterest	1000	usd
CY2023Q3	niobf	Contractual Interest ContractualInterest	130000	usd
CY2024Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	43000	usd
CY2023Q3	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1945000	usd
CY2024Q3	us-gaap	Accretion Expense AccretionExpense	44000	usd
CY2023Q3	us-gaap	Accretion Expense AccretionExpense	2075000	usd
CY2024Q2	us-gaap	Fair Value Hedge Assets At Fair Value FairValueHedgeAssetsAtFairValue	7089000	usd
CY2024Q3	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	1848000	usd
CY2024Q3	niobf	Change In Fair Value ChangeInFairValue	17000	usd
CY2024Q3	us-gaap	Fair Value Hedge Assets At Fair Value FairValueHedgeAssetsAtFairValue	5258000	usd
CY2024Q3	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	5280000	usd
CY2024Q3	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	1176000000	usd
CY2024Q3	us-gaap	Debt Instrument Increase Decrease Other Net DebtInstrumentIncreaseDecreaseOtherNet	336000000	usd
CY2024Q4	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	1176000000	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75000	shares
CY2024Q3	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	140000	usd
CY2024Q3	us-gaap	Stock Issued1 StockIssued1	133000	usd
CY2024Q3	us-gaap	Nonmonetary Transaction Gain Loss Recognized On Transfer NonmonetaryTransactionGainLossRecognizedOnTransfer	-7000	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71000	shares
CY2024Q3	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	124000	usd
CY2024Q3	us-gaap	Stock Issued1 StockIssued1	123000	usd
CY2024Q3	us-gaap	Nonmonetary Transaction Gain Loss Recognized On Transfer NonmonetaryTransactionGainLossRecognizedOnTransfer	-1000	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	71500	shares
CY2024Q3	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	118000	usd
CY2024Q3	us-gaap	Stock Issued1 StockIssued1	118000	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72000	shares
CY2024Q3	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	124000	usd
CY2024Q3	us-gaap	Stock Issued1 StockIssued1	124000	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49750	shares
CY2024Q3	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	85000	usd
CY2024Q3	us-gaap	Stock Issued1 StockIssued1	85000	usd
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	60000	shares
CY2024Q3	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	101000	usd
CY2024Q3	us-gaap	Stock Issued1 StockIssued1	108000	usd
CY2024Q3	us-gaap	Nonmonetary Transaction Gain Loss Recognized On Transfer NonmonetaryTransactionGainLossRecognizedOnTransfer	7000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2495500	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.78
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	40000	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.95
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2455500	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.76
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	18563561	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.53
CY2024Q3	niobf	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	2816742	shares
CY2024Q3	niobf	Class Of Warrant Or Right Exercise Price Granted ClassOfWarrantOrRightExercisePriceGranted	2.31
CY2024Q3	niobf	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	-447318	shares
CY2024Q3	niobf	Class Of Warrant Or Right Exercise Price Expired ClassOfWarrantOrRightExercisePriceExpired	8.94
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20932985	shares
CY2024Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.46
CY2024Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20932985	shares
CY2024Q3	us-gaap	Business Combination Contingent Consideration Arrangements Description BusinessCombinationContingentConsiderationArrangementsDescription	As consideration for entering into the previously publicly disclosed Waiver and Consent Agreement, dated September 25, 2022 (the “Lind Consent”), between the Company and Lind Global Asset Management III, LLC (“Lind III”), Lind III received, amongst other things, the right to receive additional Warrants (the “Contingent Consent Warrants”) if on September 17, 2024, the closing trading price of the Common Shares on the Toronto Stock Exchange or such other stock exchange on which such shares may then be listed, is less than C$10.00, subject to adjustments. The number of Contingent Consent Warrants to be issued, if any, is based on the Canadian dollar equivalent (based on the then current Canadian to U.S. dollar exchange rate as reported by Bloomberg, L.P.) of $5,000 divided by the five-day volume weighted average price of the Common Shares on the date of issuance.
CY2024Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2816742	shares
CY2024Q3	us-gaap	Exploration Expense ExplorationExpense	138000	usd
CY2023Q3	us-gaap	Exploration Expense ExplorationExpense	1100000	usd
CY2024Q3	niobf	Fixed Rent Expense FixedRentExpense	23000	usd
CY2023Q3	niobf	Fixed Rent Expense FixedRentExpense	23000	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	3000	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	3000	usd
CY2024Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	usd
CY2023Q3	us-gaap	Short Term Lease Cost ShortTermLeaseCost	2000	usd
CY2024Q3	us-gaap	Sublease Income SubleaseIncome	9000	usd
CY2023Q3	us-gaap	Sublease Income SubleaseIncome	6000	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	20000	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	22000	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	220000	usd
CY2024Q3	niobf	Less Amount Of Payments Representing Interest LessAmountOfPaymentsRepresentingInterest	-36000	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	184000	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	97000	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	87000	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	150000	usd
CY2024Q3	niobf	Available For Sale Securities Equity Securities Other AvailableForSaleSecuritiesEquitySecuritiesOther	4000	usd
CY2024Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	154000	usd
CY2024Q3	us-gaap	Notes Payable NotesPayable	5258000	usd
CY2024Q3	us-gaap	Other Liabilities Fair Value Disclosure OtherLiabilitiesFairValueDisclosure	4633000	usd
CY2024Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	1595000	usd
CY2024Q3	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	11486000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	2012000	usd
CY2024Q2	niobf	Available For Sale Securities Equity Securities Other AvailableForSaleSecuritiesEquitySecuritiesOther	4000	usd
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2016000	usd
CY2024Q2	us-gaap	Notes Payable NotesPayable	7089000	usd
CY2024Q2	us-gaap	Other Liabilities Fair Value Disclosure OtherLiabilitiesFairValueDisclosure	3817000	usd
CY2024Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	4016000	usd
CY2024Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	14922000	usd
CY2024Q4	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	1176000	usd
CY2024Q4	us-gaap	Debt Instrument Increase Decrease Other Net DebtInstrumentIncreaseDecreaseOtherNet	336000	usd
CY2024Q3	niobf	Accrued Cost AccruedCost	459000	usd

Files In Submission

Name	View Source	Status
0001539497-24-002408-index-headers.html	Edgar Link	pending
0001539497-24-002408-index.html	Edgar Link	pending
0001539497-24-002408.txt	Edgar Link	pending
0001539497-24-002408-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
n257410qimg001.jpg	Edgar Link	pending
n2574_x224-10q.htm	Edgar Link	pending
n2574_x224exh31-1.htm	Edgar Link	pending
n2574_x224exh31-2.htm	Edgar Link	pending
n2574_x224exh32-1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
n2574_x224-10q_htm.xml	Edgar Link	completed
n2574_x224exh32-2.htm	Edgar Link	pending
n2574_x224exh4-10.htm	Edgar Link	pending
n2574_x224exh4-3.htm	Edgar Link	pending
n2574_x224exh4-4.htm	Edgar Link	pending
n2574_x224exh4-8.htm	Edgar Link	pending
n2574_x224exh4-9.htm	Edgar Link	pending
niobf-20240930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
niobf-20240930_def.xml	Edgar Link	unprocessable
niobf-20240930_lab.xml	Edgar Link	unprocessable
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
niobf-20240930_cal.xml	Edgar Link	unprocessable
niobf-20240930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NB
NIOCORP DEVELOPMENTS LTD Stock $nb

2024 Q4 Form 10-Q Financial Statement

#000153949724002408 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NB NIOCORP DEVELOPMENTS LTD Stock $nb

2024 Q4 Form 10-Q Financial Statement

#000153949724002408 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NB
NIOCORP DEVELOPMENTS LTD Stock $nb